Moreover, in human patients, loss of GC-C signalling during IBD might cause inflammation-induced colorectal cancer and systemic genotoxicity due to higher levels of ROS production, leading to extra-intestinal cancer in lymph nodes, liver and lungs [211–213]. The gene discussed is GUCY2C; the disease is irritable bowel syndrome.